[Angiogenic gene therapy for ischemic heart disease].
Once myocardium is under hypoxia due to narrowing of coronary arteries, the myocardium produces angiogenic peptides such as fibroblast growth factors to develop collaterals to restore the blood supply to its ischemic region. Thus, if angiogenic growth factors are supplied exogenously, the development of collaterals should be facilitated, and may save myocardium from hypoxia, thereby enhancing heart function. In addition to the experiments using recombinant protein of angiogenic factors, recent reports showed that gene transfer of such angiogenic factors indeed restored blood supply into ischemic myocardium and enhanced its function, suggesting such approach being an effective new strategy for the treatment of ischemic heart disease. This brief review summarizes recent progress of angiogenic therapy.
Ueno
H
H
Department of Cardiology, Kyushu University School of Medicine.
D003097:Collateral Circulation; D016228:Endothelial Growth Factors / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000235:genetics; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors